Genmab (Otc) (GMAB)
NASDAQ:GMAB
Want to see GMAB full AI Analyst Report?
GMAB Stock Chart & Stats
$28.55
-$0.14(-0.65%)
At close: 4:00 PM EST
$28.55
-$0.14(-0.65%)
Day’s Range― - ―
52-Week Range$20.23 - $35.43
Previous CloseN/A
Volume229.76K
Average Volume (3M)2.07M
Market Cap
$14.84B
Enterprise Value$20.15B
Total Cash (Recent Filing)$1.52B
Total Debt (Recent Filing)$5.35B
Price to Earnings (P/E)18.6
Beta0.63
Next Earnings
Aug 06, 2026EPS Estimate
0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.33
Shares Outstanding623,507,200
10 Day Avg. Volume1,811,016
30 Day Avg. Volume2,069,117
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)3.28
Price to Sales (P/S)5.14
P/FCF Ratio16.65
Enterprise Value/Market Cap1.36
Enterprise Value/Revenue5.17
Enterprise Value/Gross Profit5.54
Enterprise Value/Ebitda14.20
Forecast
1Y Price Target
$35.69Price Target Upside25.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)1.16
Revenue Forecast (FY)$4.33B
Bulls Say, Bears Say
Bulls Say
Durable DARZALEX RoyaltiesLarge, recurring royalties from DARZALEX provide a durable earnings backbone. Sustained multi‑billion dollar end‑market sales translate into predictable royalty cashflows that support R&D funding and commercialization investments over multiple years, reducing reliance on one‑time financing.
EPKINLY Commercial MomentumRapid EPKINLY uptake and label expansion broaden outpatient use and addressable market. Faster adoption across geographies and reduced administration constraints support sustainable proprietary sales growth, improving prospects for future launches and lowering commercialization friction long term.
Strong Underlying ProfitabilityGenmab's antibody economics deliver high gross margins and operating leverage, enabling operating profit growth even while investing. This fundamental margin strength supports continued reinvestment in late‑stage assets and commercialization without immediately eroding core profitability over the medium term.
Bears Say
Rising LeverageA material increase in debt relative to equity raises financial risk and reduces balance sheet flexibility. Higher leverage constrains capacity for opportunistic R&D financing or M&A, increases interest and covenant sensitivity, and lengthens the time required to restore conservative capital structure.
Weakening Free Cash Flow MomentumA pronounced drop in trailing free cash flow signals weaker near‑term cash conversion despite profitability. Persistent FCF weakness could force greater reliance on external financing or equity issuance to fund stepped‑up launches and late‑stage programs, increasing dilution or financing costs.
Binary Clinical Readouts RiskOutcome dependence on several pivotal readouts creates binary upside/downside for pipeline value. Negative or delayed results would materially slow planned launches and revenue ramps, making medium‑term growth contingent on successful clinical execution amid competitive pressures.
GMAB FAQ
What was Genmab (Otc)’s price range in the past 12 months?
Genmab (Otc) lowest stock price was $20.23 and its highest was $35.43 in the past 12 months.
What is Genmab (Otc)’s market cap?
Genmab (Otc)’s market cap is $14.84B.
When is Genmab (Otc)’s upcoming earnings report date?
Genmab (Otc)’s upcoming earnings report date is Aug 06, 2026 which is in 56 days.
How were Genmab (Otc)’s earnings last quarter?
Genmab (Otc) released its earnings results on May 07, 2026. The company reported $0.083 earnings per share for the quarter, missing the consensus estimate of $0.156 by -$0.073.
Is Genmab (Otc) overvalued?
According to Wall Street analysts Genmab (Otc)’s price is currently Undervalued.
Does Genmab (Otc) pay dividends?
Genmab (Otc) does not currently pay dividends.
What is Genmab (Otc)’s EPS estimate?
Genmab (Otc)’s EPS estimate is 0.34.
How many shares outstanding does Genmab (Otc) have?
Genmab (Otc) has 623,507,200 shares outstanding.
What happened to Genmab (Otc)’s price movement after its last earnings report?
Genmab (Otc) reported an EPS of $0.083 in its last earnings report, missing expectations of $0.156. Following the earnings report the stock price went down -2.976%.
Which hedge fund is a major shareholder of Genmab (Otc)?
Currently, no hedge funds are holding shares in GMAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Genmab Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.69 (25.00% Upside)
$35.69 (25.00% Upside)
Blogger Sentiment
Bullish
GMAB Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days >0.1%
Last 30 Days ▲ 2.6%
Last 30 Days ▲ 2.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
7.22%
12-Months-Change
Fundamentals
Return on Equity
20.51%
Trailing 12-Months
Asset Growth
87.91%
Trailing 12-Months
Company Description
Genmab (Otc)
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.
GMAB Company Deck
GMAB Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum, meaningful top-line growth, improving profitability and a catalyst-rich 2026 driven by multiple late-stage readouts (EPKINLY, Rina-S, petosemtamab). Management highlighted disciplined but sizeable investments to support launches and pipeline advancement and reported faster-than-expected enrollment on key trials. Key risks discussed include near-term tax-rate volatility tied to Merus integration, substantial planned operating spend, a hypercompetitive landscape for Rina-S, and dependency on several binary clinical readouts. Overall, the positives from robust revenue/receipt growth, operating profit expansion, completed pivotal enrollment and multiple upcoming catalysts materially outweigh the outlined uncertainties.View all GMAB earnings summariesGMAB Stock 12 Month Forecast
Average Price Target
$35.69
▲(25.00% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.83% Mutual Funds
5.67% Other Institutional Investors
92.34% Public Companies and
Individual Investors